Genovis AB (publ.)

DB:5GV Stock Report

Market Cap: €136.4m

Genovis AB (publ.) Valuation

Is 5GV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 5GV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 5GV (€2.01) is trading above our estimate of fair value (€1.9)

Significantly Below Fair Value: 5GV is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 5GV?

Key metric: As 5GV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 5GV. This is calculated by dividing 5GV's market cap by their current earnings.
What is 5GV's PE Ratio?
PE Ratio56.1x
EarningsSEK 27.91m
Market CapSEK 1.56b

Price to Earnings Ratio vs Peers

How does 5GV's PE Ratio compare to its peers?

The above table shows the PE ratio for 5GV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.4x
GXI Gerresheimer
19.4x21.8%€2.2b
1SXP SCHOTT Pharma KGaA
23.2x13.9%€3.5b
PSG PharmaSGP Holding
16.6x13.6%€311.7m
XLS Xlife Sciences
6.2xn/aCHF 132.6m
5GV Genovis AB (publ.)
56.1x16.4%€1.6b

Price-To-Earnings vs Peers: 5GV is expensive based on its Price-To-Earnings Ratio (56.1x) compared to the peer average (16.4x).

Price to Earnings Ratio vs Industry

How does 5GV's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
5GV 56.1xIndustry Avg. 35.0xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 5GV is expensive based on its Price-To-Earnings Ratio (56.1x) compared to the European Life Sciences industry average (35.5x).

Price to Earnings Ratio vs Fair Ratio

What is 5GV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

5GV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio56.1x
Fair PE Ratio12.5x

Price-To-Earnings vs Fair Ratio: 5GV is expensive based on its Price-To-Earnings Ratio (56.1x) compared to the estimated Fair Price-To-Earnings Ratio (12.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 5GV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.01
€3.37
+67.6%
25.7%€4.58€2.59n/a3
Jan ’26€2.07
€3.37
+62.8%
25.7%€4.58€2.59n/a3
Dec ’25€2.21
€3.37
+52.8%
25.7%€4.58€2.59n/a3
Nov ’25€1.83
€3.34
+82.7%
26.8%€4.58€2.46n/a3
Oct ’25€2.35
€3.79
+61.3%
20.9%€4.58€3.00n/a2
Sep ’25€2.18
€3.78
+73.3%
20.9%€4.57€2.99n/a2
Aug ’25€2.52
€4.44
+76.6%
26.2%€5.61€3.28n/a2
Jul ’25€2.47
€4.42
+79.1%
26.2%€5.58€3.26n/a2
Jun ’25€3.31
€4.42
+33.8%
26.2%€5.58€3.26n/a2
May ’25€2.33
€4.36
+87.7%
24.8%€5.44€3.28n/a2
Apr ’25€2.83
€4.92
+74.1%
13.5%€5.58€4.25n/a2
Mar ’25€3.32
€6.07
+83.1%
10.3%€6.69€5.44n/a2
Feb ’25€4.52
€6.58
+45.8%
9.0%€7.05€5.74n/a3
Jan ’25€4.80
€6.58
+37.3%
9.0%€7.05€5.74€2.073
Dec ’24€4.24
€6.58
+55.5%
9.0%€7.05€5.74€2.213
Nov ’24€3.64
€6.91
+89.9%
14.7%€8.17€5.68€1.833
Oct ’24€3.96
€6.75
+70.4%
14.7%€7.98€5.54€2.353
Sep ’24€4.38
€7.33
+67.4%
8.6%€7.96€6.70€2.182
Aug ’24€3.99
€7.55
+89.5%
6.4%€8.04€7.07€2.522
Jul ’24€3.93
€7.55
+92.4%
6.4%€8.04€7.07€2.472
Jun ’24€4.48
€7.55
+68.7%
6.4%€8.04€7.07€3.312
May ’24€5.10
€7.34
+43.9%
8.5%€7.97€6.71€2.332
Apr ’24€5.61
€7.34
+30.8%
8.5%€7.97€6.71€2.832
Mar ’24€5.15
€7.34
+42.5%
8.5%€7.97€6.71€3.322
Feb ’24€5.38
€6.68
+24.2%
7.9%€7.21€6.16€4.522
Jan ’24€4.03
€6.52
+61.7%
15.5%€7.53€5.51€4.802

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 01:49
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genovis AB (publ.) is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel AlbinDanske Bank
Simon LarssonDanske Bank
Josefine PerssonNordea Markets